MedTrace Logo

Economic Evaluation of Innovative Molecular Analyses in Onco-haematology

NCT03750994 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 3960

Last updated 2018-11-23

No results posted yet for this study

Summary

To evaluate the impact of innovative molecular diagnostics on the clinical management of patients with haematological malignancies via updated Appropriate-Prescribing-Guides including Next-Generation Sequencing (NGS) panels, facilitated therapeutic orientation, and optimised use of costly novel therapeutics and risk-adapted treatment. A micro-costing approach will be used to develop flat fee tarifs for NGS analyses.

Conditions

  • Haematological Malignancy

Sponsors & Collaborators

  • Ministry of Health, France

    collaborator OTHER_GOV

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Claude Preudhomme, Professor · DRCI AP-HP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-18
Primary Completion
2020-10-31
Completion
2020-10-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03750994 on ClinicalTrials.gov